Jennifer A. Low

University of Malaya — Malaysia

Biochemistry, Genetics and Molecular Biology · Life Sciences

32h-index9.5kcitations157works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hedgehog Signaling Pathway Studies(57), Cancer-related Molecular Pathways(17), Cancer Treatment and Pharmacology(17), Chromatin Remodeling and Cancer(17), Advanced Breast Cancer Therapies(15)

Publications157 total

#552 A machine learning approach to predict acute kidney injury in hospitalised heart failure patients
Nephrology Dialysis Transplantation·2025Open Access
Safety and Tolerability of a Novel Inhaled Thiol-Saccharide Mucolytic (Fexlamose, MUC-031) in Healthy Volunteers
American Journal of Respiratory and Critical Care Medicine·2025· 1 cited
WCN25-628 RISK FACTORS FOR ACUTE KIDNEY INJURY AND THE PROGRESSION INTO ACUTE KIDNEY DISEASE IN HOSPITALISED HEART FAILURE PATIENTS: A SINGLE-CENTRE, RETROSPECTIVE STUDY
Kidney International Reports·2025Open Access
Introduction: Shakespeares for a Ukraine at War
Shakespeare bulletin·2024
<i>Shakespeare’s White Others</i>. By <scp>David Sterling Brown</scp>
Shakespeare Quarterly·2024
Lady M dir. by Emma Jaster (review)
Shakespeare bulletin·2023
1776 (review)
Theatre Journal·2023
Supplementary Figure Legends from An Oncogenic &lt;i&gt;NTRK&lt;/i&gt; Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
2023Open Access
Supplementary Figures 1 - 5 from An Oncogenic &lt;i&gt;NTRK&lt;/i&gt; Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
2023Open Access
Data from An Oncogenic &lt;i&gt;NTRK&lt;/i&gt; Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
2023Open Access
Supplementary Figure Legends from An Oncogenic &lt;i&gt;NTRK&lt;/i&gt; Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
2023Open Access
Supplementary Figures 1 - 5 from An Oncogenic &lt;i&gt;NTRK&lt;/i&gt; Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
2023Open Access
Data from An Oncogenic &lt;i&gt;NTRK&lt;/i&gt; Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
2023Open Access
Supplementary Figure 1 from Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors
2023Open Access
Related CCR Translation from Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
2023Open Access
Supplementary Figure 3 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Related CCR Translation from Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
2023Open Access
Data from Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
2023Open Access
Supplementary Figure 4 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure 3 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Charles M. Rudin(9), Richard Graham(9), Arlene Berman(9), Seth M. Steinberg(9), Sandra M. Swain(9), Robert L. Yauch(8), Patricia LoRusso(8), Howard Mackey(6), Daniel D. Von Hoff(6), Frédéric J. de Sauvage(6), Josina C. Reddy(5), Ilsung Chang(5), Mitesh J. Borad(4), Christine L. Hann(4), Walter C. Darbonne(4), Kenn L. Zerivitz(4), Robert C. Doebele(4), Robert J. Kinders(4), Larry Rubinstein(4), Ralph E. Parchment(4)